Cyclerion Therapeutics Q3 2025 Earnings Report

Cyclerion Therapeutics EPS Results

• Actual EPS: -$0.30
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Cyclerion Therapeutics Revenue Results

• Actual Revenue: $0.88 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Cyclerion Therapeutics Announcement Details

• Quarter: Q3 2025
• Date: 10/30/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Cyclerion Therapeutics (NASDAQ:CYCN) is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction. In parallel, Cyclerion is advancing CY6463, a central nervous system-penetrant sGC stimulator, in neurocognitive and neurodegenerative disorders. Both programs are supported by preclinical and early-stage clinical data suggesting potential benefits in modulating cGMP signaling across multiple organ systems. Cyclerion leverages a modular research platform to optimize pharmacokinetic and pharmacodynamic properties for both systemic and brain-targeted therapies.

Founded in May 2018 as a spin-out from Ironwood Pharmaceuticals, Cyclerion is headquartered in Cambridge, Massachusetts, with research collaborations and clinical sites spanning the United States and Europe. The company is led by a management team with extensive experience in drug discovery, clinical development and regulatory affairs. Cyclerion continues to build on its translational science capabilities to expand its pipeline of sGC-based therapeutics and explore strategic partnerships to advance its programs toward regulatory milestones.